Clinical Trial Update: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety, efficacy, and pharmacokinetics of ARGX-113 in patients with generalized Myasthenia Gravis. The study has completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• ARGX-113

Snippet

Sponsor: argenx | Conditions: Myasthenia Gravis | Phase 2 | Status: COMPLETED | Results posted: 2021-01-08